Wednesday , March 29 2017
Home / Cannabis Based Medicine

Cannabis Based Medicine

Cannabics Announces Commercialization of Cannabinoids-Based Personalized Diagnostics for Cancer Patients

BETHESDA, Maryland, Feb. 6, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) today announced it will begin providing personalized cannabinoid anti-tumor tests for cancer patients. The diagnostic tests are based on liquid biopsies of patients suffering from any kind of cancer. The test uses CTC technology that collects cancer cells from patients’ …

Read More »

GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study

London, UK, 7 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination …

Read More »

Cannabics Announces Specific Ratios of Cannabinoids Led to Apoptosis in MD-MB-231 Breast Cancer Cell Viability

BETHESDA, Maryland, Dec. 1, 2016 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that results from the company’s Cancer HTS research indicates that specific ratios of Cannabinoids led to Apoptosis in MDA-MB-231 Breast Cancer cell viability. Cannabics Pharmaceuticals is currently developing a personalized treatment based upon screening of patients’ biopsy …

Read More »

Therapix Develops Formulations for a Tablet for Sublingual Administration of THC for Pharmaceutical Use

TEL AVIV, Israel, October 31, 2016 /PRNewswire/ — Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced the successfully completion of the development phase of a unique formulation of a tablet for sublingual administration for pharmaceutical use. The tablet is …

Read More »

Cannabics Discovers Specific Ratios of THC/CBD Effectuate Reduction in U87MG Glioblastoma Cell Viability

BETHESDA, Maryland, October 20, 2016 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that results from the company’s latest cancer HTS research overtly conclude that, depending upon the THC/CBD ratio, specific Cannabis extracts are directly contributive to reducing U87MG glioblastoma cell viability. The Company expects that results on additional types …

Read More »

CNF Presents Cannabis in Epilepsy: A Symposium Designed to Bridge the Gap in Communication

MINNEAPOLIS, Oct. 19, 2016 /PRNewswire-USNewswire/ — The Child Neurology Foundation (CNF) is poised to welcome members of the Child Neurology Society (CNS) interested in seeking a deeper understanding of the current science, family experience and advocacy efforts surrounding the use of cannabis for the treatment of epilepsy. The organization will …

Read More »

Medical Genomics Partners with Industry Leaders to Develop Genomics-Based Safety and Quality Standards for Medical Cannabis

WOBURN, Mass.–(BUSINESS WIRE)–Medicinal Genomics (MGC), an innovative molecular information company focused on safety, research, and genetics of therapeutic plants, is partnering with a preliminary group of twelve leading cultivators and processors to develop fully-validated, genomics-based safety and quality standards for medical cannabis. The lack of consistency of strains from the …

Read More »

FDA Approves Insys’ Cannabis-Based Drug for Cancer, AIDS-Related Weight Loss

PHOENIX, July 05, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys’ dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (“THC”).  Syndros is …

Read More »

GW Pharma’s Epidiolex Succeeds in Late-Stage Lennox-Gastaut Syndrome Study

LONDON, June 27, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its …

Read More »

FDA Grants Orphan Drug Designation to GW Pharmaceuticals’ CBD for the Treatment of Tuberous Sclerosis Complex

LONDON, April 21, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for cannabidiol …

Read More »